Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Levation Pharma Initiates Phase I/II Clinical Trial of LEV102 for Acquired Blepharoptosis
Details : LEV102 (oxymetazoline) is an adrenergic α1- and α2-agonist and a direct-acting sympathomimetic, causing vasoconstriction of dilated arterioles and reduces blood flow. It is currently being investigated in phase I/II clinical trial for acquired blepharo...
Brand Name : LEV102
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 27, 2023
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Sato Yakuhin Kogyo Co., Ltd
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Details : Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trial...
Brand Name : Rhofade
Molecule Type : Small molecule
Upfront Cash : $5.0 million
December 21, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Sato Yakuhin Kogyo Co., Ltd
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Afrin® (oxymetazoline hydrochloride) provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies. Afrin® Extra Moisturizing Stuffy Nose Pump Mist, for ages two to six years old unblocks a stuffy nose fast.
Brand Name : Afrin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : RVL Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals, Inc.
Details : As another company invested in optimal patient health, RVL Pharmaceuticals offers appropriate patients a nonsurgical solution for acquired ptosis and provides results in as fast as 5 minutes with UPNEEQ (oxymetazoline hydrochloride ophthalmic solution).
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 30, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : RVL Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Athyrium Capital
Deal Size : $24.0 million
Deal Type : Private Placement
RVL Pharmaceuticals Plc Announces Insider and Athyrium-Led Financing
Details : The financing reflects in the brand and enhances the financial position as build momentum with the expanded launch of UPNEEQ (oxymetazoline hydrochloride). Provider and patient feedback continue to be positive as UPNEEQ awareness grows.
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 04, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Athyrium Capital
Deal Size : $24.0 million
Deal Type : Private Placement
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Novan
Deal Size : $51.0 million
Deal Type : Acquisition
Novan Acquires EPI Health, a Specialty Dermatology Company
Details : Acquisition forward integrates Novan with complementary commercial infrastructure to drive commercial launch of SB206, subject to regulatory approval, for the treatment of molluscum contagiosum.
Brand Name : Rhofade
Molecule Type : Small molecule
Upfront Cash : $27.5 million
March 11, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Novan
Deal Size : $51.0 million
Deal Type : Acquisition
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Athyrium Capital Management
Deal Size : Undisclosed
Deal Type : Financing
Details : The financing provides the Company with additional cash to support the commercialization of Upneeq. As a first-in-class treatment for acquired ptosis, Upneeq offers patients and clinicians a convenient non-surgical therapeutic option.
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 07, 2021
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Athyrium Capital Management
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Alora Pharmaceuticals
Deal Size : $170.0 million
Deal Type : Divestment
Details : Osmotica will retain the RVL Pharmaceuticals business focused on ophthalmology and aesthetics, led by its flagship product, UPNEEQ (Oxymetazoline Hydrochloride).
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : $110.0 million
June 25, 2021
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Alora Pharmaceuticals
Deal Size : $170.0 million
Deal Type : Divestment
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acquired ptosis.
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2020
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : RVL Pharmaceuticals
Deal Size : $89.0 million
Deal Type : Licensing Agreement
Details : Under the agreement Santen will be responsible for further development of RVL-1201 and regulatory approvals as well as commercialization in its licensed territories under the agreement.
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : $25.0 million
July 28, 2020
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : RVL Pharmaceuticals
Deal Size : $89.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
